NicOx to pursue naproxinod in the US
This article was originally published in Scrip
NicOx is refusing to give up on its lead product candidate naproxcinod. The French company is pursuing its appeal of the US FDA decision last year not to approve the osteoarthritis candidate, despite withdrawing the product's European filing two weeks ago. NicOx said it is currently finalising the submission of the supporting information for the appeal.